Our findings from the experiments employing novel T-type Ca2+ channel blockers, 6-PNG and KTt-45, Cav3.2-knockout mice and a CSE inhibitor provide ultimate evidence for the role of the CSE/H2S/Cav3.2 axis in cystitis-related bladder pain, and ascertain that Cav3.2 is a promising therapeutic target for treatment of bladder pain in IC/BPS patients. Here, CACNA1H is linked to Bartsocas-Papas syndrome 1.